Familial Lipoprotein Lipase DeficiencySymptoms, Doctors, Treatments, Advances & More
Familial Lipoprotein Lipase Deficiency Overview
Learn About Familial Lipoprotein Lipase Deficiency
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Office
Joseph Witztum is an Endocrinologist practicing medicine in La Jolla, California. Dr. Witztum is rated as an Elite provider by MediFind in the treatment of Familial Lipoprotein Lipase Deficiency. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Apolipoprotein C2 Deficiency, Familial Lipoprotein Lipase Deficiency, Familial Hypertriglyceridemia, and Antigen-Peptide-Transporter 2 Deficiency.
Office
Sotirios Tsimikas is a Cardiologist practicing medicine in La Jolla,, California. Dr. Tsimikas is rated as an Elite provider by MediFind in the treatment of Familial Lipoprotein Lipase Deficiency. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses High Cholesterol, Apolipoprotein C2 Deficiency, Familial Lipoprotein Lipase Deficiency, Percutaneous Coronary Intervention (PCI), and Stent Placement.
Baylor Medicine Atherosclerosis
Christie Ballantyne is a Cardiologist practicing medicine in Houston, Texas. He has been practicing medicine for over 44 years. Dr. Ballantyne is rated as an Elite provider by MediFind in the treatment of Familial Lipoprotein Lipase Deficiency. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Familial Hypertriglyceridemia, High Cholesterol, Atherosclerosis, Coronary Artery Bypass Graft (CABG), and Heart Bypass Surgery.
Summary: This is an open-label, single-arm, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid nanoparticles targeting APOC3, in adult participants (18-55 years) with familial chylomicronemia syndrome (FCS).
Summary: Lipoprotein lipase (LPL) is an enzyme that plays an important role in removing triglycerides (TG) (molecules that transport dietary fat) from the blood. Patients with LPL deficiency (LPLD) display during their whole life very high plasma TG levels often associated with episodes of postprandial abdominal pain, malaise, blurred vision, dizziness (hyperchylomicronemia syndrome) that may lead to recur...